BrainStorm Announces New Shareholders Conference Call Date to Discuss Upcoming Positive Developments


BrainStorm Announces New Shareholders Conference Call Date to Discuss Upcoming Positive Developments

NEW YORK & PETACH TIKVAH, Israel--(BUSINESS WIRE)-- BrainStorm Cell Therapeutics (OTC.QB: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, announced today that it has rescheduled its previously planned shareholders conference call. The call will be held on Monday, January 14, 2013 at 8:00 a.m. EST in Hebrew and at 8:45 a.m. EST in English. The company's senior management team will discuss some significant positive company developments to be released shortly.

Callers may participate in the conference call, in Hebrew at 08:00 a.m. EST (15:00 p.m. Israel time), by dialing:
USA: 1-888-407-2553
Israel: 03-9180610
International: +972-3-9180610

Callers may participate in the conference call, in English at 08:45 a.m. EST, by dialing:
USA: 1-888-668-9141
Israel: 03-9180609
International: +972-3-9180609

Callers are invited to ask relevant questions during the conference call. Questions may also be pre-submitted to prior to 7:00 a.m. EST Thursday, January 10, 2013.

A recording of the conference will be available for download by Wednesday, January 16, 2013 from the company's website.

About BrainStorm Cell Therapeutics, Inc.

BrainStorm Cell Therapeutics, Inc. is a biotechnology company engaged in the development of first-of-its-kind adult stem cell therapies derived from autologous bone marrow cells for the treatment of neurodegenerative diseases. The Company holds the rights to develop and commercialize its NurOwn technology through an exclusive, worldwide licensing agreement with Ramot, the technology transfer company of Tel Aviv University. For more information, visit the company's website at

Safe Harbor Statement

Statements in this announcement other than historical data and information constitute "forward-looking statements" and involve risks and uncertainties that could cause BrainStorm Cell Therapeutics, Inc.'s actual results to differ materially from those stated or implied by such forward-looking statements. Terms and phrases such as "may," "should," "would," "could," "will," "expect," "likely," "believe," "plan," "estimate," "predict," "potential,"and similar terms and phrases are intended to identify these forward-looking statements.The potential risks and uncertainties include, without limitation, risks associated with BrainStorm's limited operating history, history of losses; minimal working capital, dependence on its license to Ramot's technology; ability to adequately protect the technology; dependence on key executives and on its scientific consultants; ability to obtain required regulatory approvals; and other factors detailed in BrainStorm's annual report on Form 10-K and quarterly reports on Form 10-Q available at factors should be considered carefully, and readers should not place undue reliance on BrainStorm's forward-looking statements.The forward-looking statements contained in this press release are based on the beliefs, expectations and opinions of management as of the date of this press release. We do not assume any obligation to update forward-looking statements to reflect actual results or assumptions if circumstances or management's beliefs, expectations or opinions should change, unless otherwise required by law. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance or achievements.


BrainStorm Cell Therapeutics, Inc. (OTC.QB: BCLI)
Dr. Adrian Harel, CEO
Phone: +972-3-9236384

KEYWORDS: United States North America New York Middle East Israel


The article BrainStorm Announces New Shareholders Conference Call Date to Discuss Upcoming Positive Developments originally appeared on

Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.